Premium
Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers
Author(s) -
Ryn Joanne,
KinkEiband Monika,
Kuritsch Ingrid,
Feifel Ulrich,
Hanft Gertraud,
Wallenstein Gudrun,
Trummlitz Guenter,
Pairet Michel
Publication year - 2004
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270004266623
Subject(s) - meloxicam , aspirin , crossover study , medicine , platelet , thromboxane b2 , pharmacology , cyclooxygenase , thromboxane , anesthesia , chemistry , biochemistry , placebo , enzyme , alternative medicine , pathology
This study determined if meloxicam, a selective cyclooxygenase (COX)‐2 inhibitor, interferes with the antiplatelet effect of aspirin using platelet aggregation and thromboxane (Tx) B 2 endpoints in healthy volunteers. Eight male and 8 female volunteers participated in this open‐label, randomized, two‐treatment, two‐way crossover trial. Treatment 1 was meloxicam (15 mg qd) over 4 days, and then aspirin (100 mg qd) was ingested 2 hours after meloxicam for an additional 7 days. Blood samples were taken 2, 6, and 24 hours after the last dose. Treatment 2 consisted of only aspirin (100 mg) over 2 days. Samples were taken at the same time points. Each subject received both treatments with a 2‐week washout between the treatment periods. Treatments were safe and well tolerated. The initial 4‐day treatment with meloxicam had no effect on platelet aggregation but reduced serum TxB 2 by 64% ± 19%. Addition of aspirin (100 mg qd) for 7 days resulted in complete inhibition of aggregation and TxB 2 for 24 hours. Two‐day treatment with only 100 mg aspirin also resulted in complete inhibition of platelet aggregation and TxB 2 . These results indicate that meloxicam does not affect the ability of aspirin to inhibit COX‐1 in platelets, thereby allowing aspirin to effectively prevent platelet aggregation and reduce TxB 2 levels, and that meloxicam is selective for COX‐2